Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist

Abbott Laboratories will pay $385 million to settle claims related to contamination at its Michigan baby formula plant, which caused a 2022 shortage. The settlement does not admit fault, according to the company. The plant was closed and later reopened after an FDA investigation.

Abbott Laboratories will pay $385 million to settle allegations of false claims related to infant formula manufacturing. The DOJ claims Abbott submitted false claims to federal programs from 2018 to 2022, while Abbott denies wrongdoing. The settlement resolves issues linked to a 2022 recall and plant shutdown that worsened a national formula shortage.

Abbott Laboratories will pay $385 million to resolve allegations of submitting false claims to federal and state programs. The U.S. Attorney's office claimed Abbott failed to meet safety standards for infant formula and nutritional therapy products between 2018 and 2022. The settlement includes $348.7 million to the U.S. and $36.3 million to certain states.

Abbott Laboratories will pay $385 million to settle a lawsuit over its 2022 plant closure and formula recall. The FDA and CDC investigated the recall but found no definitive link to infant deaths. The settlement resolves federal and state claims.

Abbott Laboratories agreed to a $385M settlement with the U.S. DOJ over unsanitary conditions at its Sturgis baby formula factory, which led to a 2022 recall and national shortage. The settlement resolves claims of selling contaminated formula through government programs. Three whistleblowers will receive $69M. Abbott denies liability and faults.

Abbott Laboratories will pay $385 million to settle a case regarding contamination at its Sturgis, MI baby formula plant. The plant, the largest in the U.S., was closed in 2022 due to safety concerns, causing formula shortages. The settlement follows criticism from former FDA director Dr. Robert Califf.